CC BY-NC-ND 4.0 · Journal of Child Science 2018; 08(01): e124-e127
DOI: 10.1055/s-0038-1667348
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Assessment and Management of Over-Activity and Sleep Disorder in Mucopolysaccharidoses

Dougal Julian Hare
1   School of Psychology, Cardiff University, Cardiff, Wales, United Kingdom
,
Louise Mahon
2   Manchester Mental Health and Social Care NHS Trust, Manchester, United Kingdom
,
Stewart Rust
3   Department of Paediatric Psychosocialogy, Royal Manchester Children's Hospital, Manchester, United Kingdom
› Author Affiliations
Further Information

Publication History

25 October 2017

18 April 2018

Publication Date:
03 October 2018 (online)

Abstract

There is a growing awareness, based on both research and clinical studies, that abnormal sleep and circadian functioning are associated with the various forms of mucopolysaccharidoses (MPS), with sleep respiratory problems seemingly common in many forms of MPS. In the case of MPS III, there is evidence of syndrome-specific sleep disturbance related to an abnormal and possibly unique circadian rhythm. The presence of such patterns of sleep and activity has detrimental consequences for both the person with MPS and also invariably for her/his family and carers. On the basis of current evidence, routine assessment of sleep functioning is clearly warranted for all children with MPS III together with appropriate medical and behavioral interventions as required.

 
  • References

  • 1 Udwin O, Dennis J. Psychological and behavioural phenotypes of genetically determined syndromes: a review of research findings. In: O'Brien G, Yule W. , eds. Behavioural Phenotypes. Cambridge, UK: Cambridge University Press; 1995: 35-44
  • 2 Brown MB, Trivette PS. Mucopolysaccharide disorders. In: Phelps L. , ed. Health-Related Disorders in Children and Adolescents: A Guidebook for Understanding and Educating. Washington DC: American Psychological Association; 1998: 442-452
  • 3 Wraith JE, Scarpa M, Beck M. , et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008; 167 (03) 267-277
  • 4 Dykens EM. Measuring behavioral phenotypes: provocations from the “new genetics”. Am J Ment Retard 1995; 99 (05) 522-532
  • 5 Wolfenden C, Wittkowski A, Hare DJ. Symptoms of autism spectrum disorder (ASD) in individuals with mucopolysaccharide disease type III (Sanfilippo syndrome): asystematic review. J Autism Dev Disord 2017; 47 (11) 3620-3633
  • 6 Cross EM, Hare DJ. Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders. J Inherit Metab Dis 2013; 36 (02) 189-200
  • 7 Valstar MJ, Ruijter GJ, van Diggelen OP, Poorthuis BJ, Wijburg FA. Sanfilippo syndrome: a mini-review. J Inherit Metab Dis 2008; 31 (02) 240-252
  • 8 Cross EM, Grant S, Jones S. , et al. An investigation of the middle and late behavioural phenotypes of Mucopolysaccharidosis Type-III. J Neurodev Disord 2014; 6 (01) 46
  • 9 Davison JE, Kearney S, Horton J, Foster K, Peet AC, Hendriksz CJ. Intellectual and neurological functioning in Morquio syndrome (MPS IVa). J Inherit Metab Dis 2013; 36 (02) 323-328
  • 10 Bax MC, Colville GA. Behaviour in mucopolysaccharide disorders. Arch Dis Child 1995; 73 (01) 77-81
  • 11 Mahon L. . Objective Assessment of Sleep in Neurodevelopmental Disorders: A Study of Children with Mucopolysaccharidosis Type III [DClinPsy. Thesis]. Manchester, UK: University of Manchester; 2012
  • 12 Nashed A, Al-Saleh S, Gibbons J. , et al. Sleep-related breathing in children with mucopolysaccharidosis. J Inherit Metab Dis 2009; 32 (04) 544-550
  • 13 Santamaria F, Andreucci MV, Parenti G. , et al. Upper airway obstructive disease in mucopolysaccharidoses: polysomnography, computed tomography and nasal endoscopy findings. J Inherit Metab Dis 2007; 30 (05) 743-749
  • 14 Lin HY, Chen MR, Lin CC. , et al. Polysomnographic characteristics in patients with mucopolysaccharidoses. Pediatr Pulmonol 2010; 45 (12) 1205-1212
  • 15 Mariotti P, Della Marca G, Iuvone L. , et al. Sleep disorders in Sanfilippo syndrome: a polygraphic study. Clin Electroencephalogr 2003; 34 (01) 18-22 (electroencephalography)
  • 16 Fraser J, Gason AA, Wraith JE, Delatycki MB. Sleep disturbance in Sanfilippo syndrome: a parental questionnaire study. Arch Dis Child 2005; 90 (12) 1239-1242
  • 17 Mahon LV, Lomax M, Grant S. , et al. Assessment of sleep in children with mucopolysaccharidosis type III. PLoS One 2014; 9 (02) e84128
  • 18 Colville GA, Watters JP, Yule W, Bax M. Sleep problems in children with Sanfilippo syndrome. Dev Med Child Neurol 1996; 38 (06) 538-544
  • 19 Canal MM, Wilkinson FL, Cooper JD, Wraith JE, Wynn R, Bigger BW. Circadian rhythm and suprachiasmatic nucleus alterations in the mouse model of mucopolysaccharidosis IIIB. Behav Brain Res 2010; 209 (02) 212-220
  • 20 Guerrero JM, Pozo D, Diaz-Rodriguez JL, Martinez-Cruz F, Vela-Campos F. Impairment of the melatonin rhythm in children with Sanfilippo syndrome. J Pineal Res 2006; 40 (02) 192-193
  • 21 Mumford RA, Mahon LV, Jones S, Bigger B, Canal M, Hare DJ. Actigraphic investigation of circadian rhythm functioning and activity levels in children with mucopolysaccharidosis type III (Sanfilippo syndrome). J Neurodev Disord 2015; 7 (01) 31
  • 22 Lack LC, Bootzin RR. Circadian rhythm factors in insomnia and their treatment. In Perlis ML, Lichstein KL. , eds. Treating Sleep Disorders: Principles and Practice of Behavioral Sleep Medicine. Hobocken, NJ: John Wiley & Son; ; 200: 305-343
  • 23 Spruyt K, Curfs LMG. Non-pharmacological management of problematic sleeping in children with developmental disabilities. Dev Med Child Neurol 2015; 57 (02) 120-136
  • 24 Priday LJ, Byrne C, Totsika V. Behavioural interventions for sleep problems in people with an intellectual disability: a systematic review and meta-analysis of single case and group studies. J Intellect Disabil Res 2017; 61 (01) 1-15
  • 25 Muenzer J, Wraith JE, Clarke LA. ; International Consensus Panel on Management and Treatment of Mucopolysaccharidosis I. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009; 123 (01) 19-29
  • 26 Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007; 120 (02) 405-418
  • 27 Malm G, Månsson JE. Mucopolysaccharidosis type III (Sanfilippo disease) in Sweden: clinical presentation of 22 children diagnosed during a 30-year period. Acta Paediatr 2010; 99 (08) 1253-1257
  • 28 Tchan MC, Sillence D. Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III. J Intellect Dev Disabil 2009; 34 (03) 275-279